Scott joined 5AM Ventures in 2003 as a Venture Partner and became a Managing Partner in 2004.
He has over three decades of healthcare management experience with strategic leadership responsibilities that led to FDA approval of three U.S. New Drug Applications (Omniscan™, Teslascan® and Cubicin®) and he has entered multiple drug candidates into clinical trials.
Scott has served as Chairman and CEO of Cubist Pharmaceuticals (acquired by Merck), President and CEO of Nycomed Salutar, and has also held various R&D positions at Salutar and Catalytica. Also, he formerly served as Board Chairman of Relypsa (NASDAQ: RLYP, acquired by Vifor Pharma), Achaogen (NASDAQ: AKAO), and Novira (acquired by Johnson & Johnson) and currently serves as Board Chairman of Rennovia, Kinestral, and Cidara (NASDAQ: CDTX). He also has served on the Boards of Epirus (NASDAQ: EPRS) and Pulmatrix. Dr. Rocklage was formerly Executive Chairman of Ilypsa (acquired by Amgen), Miikana (acquired by EntreMed) and Semprus (acquired by Teleflex).
He received his B.S. in Chemistry from the University of California, Berkeley and his PhD in Chemistry from the Massachusetts Institute of Technology where he conducted research in the laboratory of Richard R. Schrock (Nobel Prize in Chemistry in 2005).